NEW YORK – AnPac Bio-Medical Science said on Thursday that it has signed an agreement with Keystone Capital Partners for a preferred stock investment for an aggregate purchase price of $7 million.
The Shanghai-based firm will use the funding to advance its Cancer Differentiation Analysis (CDA) technology to provide cost-effective, early detection screening and testing of 26 cancers.
According to a prospectus summary filed with the US Securities and Exchange Commission, AnPac will offer 700,000 shares at a price of $10.00 per share to Keystone.